Nancy L Keating1, Pang-Hsiang Liu2, A James O'Malley2, Stephen J Freedland3, Matthew R Smith4. 1. Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. Electronic address: keating@hcp.med.harvard.edu. 2. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 3. Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA; Durham Veterans Affairs Medical Center, Durham, NC, USA. 4. Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Androgen-deprivation therapy (ADT) for prostate cancer (PCa) is associated with decreased insulin sensitivity and increased diabetes risk among nondiabetic men. Few data are available about the effects of ADT on diabetes control among men with diabetes. OBJECTIVE: We examined care for men who had diabetes at the time of PCa diagnosis to assess the effect of ADT on diabetes control, as measured by hemoglobin A1c (HbA1c) levels and the intensification of diabetes pharmacotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study using US Department of Veterans Affairs registry data and administrative data to assess HbA1c levels and intensification of diabetes pharmacotherapy among 2237 pairs of propensity-matched men with PCa and diabetes who were or were not treated with ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We calculated the difference in difference of HbA1c levels at baseline and at 1 and 2 yr in the two groups, compared using a paired Student t test. We used a Cox proportional hazards model to estimate time to intensification of diabetes pharmacotherapy. RESULTS AND LIMITATIONS: The mean HbA1c at baseline was 7.24 (standard error [SE]: 0.05) for the ADT group and 7.24 (SE: 0.04) for the no-ADT group. HbA1c increased at 1 yr for men treated with ADT to 7.38 (SE: 0.04) and decreased among men not treated with ADT to 7.14 (SE: 0.04), for a difference in differences of +0.24 (p=0.008). Results were similar at 2 yr (p=0.03). The worsening HbA1c control occurred despite ADT being associated with an increased hazard of addition of diabetes medication (adjusted hazard ratio: 1.20; 95% confidence interval, 1.09-1.32). The limitation of this study was that it was observational and relied on administrative data. CONCLUSIONS: ADT is associated with worsening of diabetes control and increases in HbA1c levels despite the use of additional diabetes medications.
BACKGROUND: Androgen-deprivation therapy (ADT) for prostate cancer (PCa) is associated with decreased insulin sensitivity and increased diabetes risk among nondiabetic men. Few data are available about the effects of ADT on diabetes control among men with diabetes. OBJECTIVE: We examined care for men who had diabetes at the time of PCa diagnosis to assess the effect of ADT on diabetes control, as measured by hemoglobin A1c (HbA1c) levels and the intensification of diabetes pharmacotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study using US Department of Veterans Affairs registry data and administrative data to assess HbA1c levels and intensification of diabetes pharmacotherapy among 2237 pairs of propensity-matched men with PCa and diabetes who were or were not treated with ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We calculated the difference in difference of HbA1c levels at baseline and at 1 and 2 yr in the two groups, compared using a paired Student t test. We used a Cox proportional hazards model to estimate time to intensification of diabetes pharmacotherapy. RESULTS AND LIMITATIONS: The mean HbA1c at baseline was 7.24 (standard error [SE]: 0.05) for the ADT group and 7.24 (SE: 0.04) for the no-ADT group. HbA1c increased at 1 yr for men treated with ADTto 7.38 (SE: 0.04) and decreased among men not treated with ADTto 7.14 (SE: 0.04), for a difference in differences of +0.24 (p=0.008). Results were similar at 2 yr (p=0.03). The worsening HbA1c control occurred despite ADT being associated with an increased hazard of addition of diabetes medication (adjusted hazard ratio: 1.20; 95% confidence interval, 1.09-1.32). The limitation of this study was that it was observational and relied on administrative data. CONCLUSIONS:ADT is associated with worsening of diabetes control and increases in HbA1c levels despite the use of additional diabetes medications.
Authors: David B Sacks; David E Bruns; David E Goldstein; Noel K Maclaren; Jay M McDonald; Marian Parrott Journal: Clin Chem Date: 2002-03 Impact factor: 8.327
Authors: Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai Journal: Circulation Date: 2010-02-01 Impact factor: 29.690
Authors: Nancy L Keating; Mary Beth Landrum; Bruce E Landon; John Z Ayanian; Catherine Borbas; Robert Wolf; Edward Guadagnoli Journal: Med Care Date: 2004-09 Impact factor: 2.983
Authors: Nancy L Keating; Mary Beth Landrum; Bruce E Landon; John Z Ayanian; Catherine Borbas; Edward Guadagnoli Journal: Health Serv Res Date: 2003-12 Impact factor: 3.402
Authors: Gregory S Cooper; Beth Virnig; Carrie N Klabunde; Nicola Schussler; Jean Freeman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Adrien N Bernstein; Jonathan E Shoag; Ron Golan; Joshua A Halpern; Edward M Schaeffer; Wei-Chun Hsu; Paul L Nguyen; Art Sedrakyan; Ronald C Chen; Scott E Eggener; Jim C Hu Journal: J Urol Date: 2017-12-26 Impact factor: 7.450
Authors: Huei-Ting Tsai; Nancy L Keating; Stephen K Van Den Eeden; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Matthew R Smith; Arnold L Potosky Journal: J Urol Date: 2014-12-15 Impact factor: 7.450
Authors: Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub Journal: Circulation Date: 2019-03-26 Impact factor: 29.690
Authors: Jiun-Ruey Hu; Meredith S Duncan; Alicia K Morgans; Jonathan D Brown; Wouter C Meijers; Matthew S Freiberg; Joe-Elie Salem; Joshua A Beckman; Javid J Moslehi Journal: Arterioscler Thromb Vasc Biol Date: 2020-01-23 Impact factor: 8.311
Authors: K Mitsuzuka; A Kyan; T Sato; K Orikasa; M Miyazato; H Aoki; N Kakoi; S Narita; T Koie; T Namima; S Toyoda; Y Fukushi; T Habuchi; C Ohyama; Y Arai Journal: Prostate Cancer Prostatic Dis Date: 2015-10-27 Impact factor: 5.554